RESUMEN
BACKGROUND: There is no prognostic index for primary cutaneous T-cell lymphomas such as mycosis fungoides (MF) and Sezary syndrome (SS). METHOD: Two prognostic indices were developed for early (IA-IIA) and late stage (IIB-IVB) disease based on multivariate data from 1502 patients. End-points included overall survival (OS) and progression free survival (PFS). External validation included 1221 patients. FINDINGS: Significant adverse prognostic factors at diagnosis consisted of male gender, age >60, plaques, folliculotropic disease and stage N1/Nx for early stage, and male gender, age >60, stages B1/B2, N2/3 and visceral involvement for late stage disease. Using these variables we constructed two separate models each defined using 3 distinct groups for early and late stage patients: 0-1 (low risk), 2 (intermediate risk), and 3-5 factors (high risk). 10 year OS in the early stage model was 90.3% (low), 76.2% (intermediate) and 48.9% (high) and for the late stage model 53.2% (low), 19.8% (intermediate) and 15.0% (high). For the validation set significant differences in OS and PFS in early stage patients (both p<0.001) were also noted. In late stage patients, only OS differed between the groups (p=0.002). INTERPRETATION: This proposed cutaneous lymphoma prognostic index provides a model for prediction of OS in early and late stage MF/SS enabling rational therapeutic choices and patient stratification in clinical trials.
Asunto(s)
Micosis Fungoide/diagnóstico , Síndrome de Sézary/diagnóstico , Neoplasias Cutáneas/diagnóstico , Biomarcadores de Tumor/sangre , Supervivencia sin Enfermedad , Femenino , Humanos , Estimación de Kaplan-Meier , L-Lactato Deshidrogenasa/sangre , Masculino , Persona de Mediana Edad , Análisis Multivariante , Micosis Fungoide/sangre , Micosis Fungoide/mortalidad , Micosis Fungoide/patología , Micosis Fungoide/terapia , Estadificación de Neoplasias , Modelos de Riesgos Proporcionales , Factores de Riesgo , Síndrome de Sézary/sangre , Síndrome de Sézary/mortalidad , Síndrome de Sézary/patología , Síndrome de Sézary/terapia , Neoplasias Cutáneas/sangre , Neoplasias Cutáneas/mortalidad , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/terapia , Factores de TiempoRESUMEN
BACKGROUND: Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors. It has activity in cutaneous T-cell lymphoma (CTCL) and has been approved by the European Medicines Agency since 1999 for treatment of the skin manifestations of advanced-stage (IIB-IVB) CTCL in adult patients refractory to at least one systemic treatment. In vivo bexarotene produces primary hypothyroidism which may be managed with thyroxine replacement. It also affects lipid metabolism, typically resulting in raised triglycerides, which requires prophylactic lipid-modification therapy. Effects on neutrophils, glucose and liver function may also occur. These side-effects are dose dependent and may be controlled with corrective therapy or dose adjustments. OBJECTIVES: To produce a U.K. statement outlining a bexarotene dosing schedule and monitoring protocol to enable bexarotene prescribers to deliver bexarotene safely for optimal effect. METHODS: Leaders from U.K. supraregional centres produced this consensus statement after a series of meetings and a review of the literature. RESULTS: The statement outlines a bexarotene dosing schedule and monitoring protocol. This gives instructions on monitoring and treating thyroid, lipid, liver, blood count, creatine kinase, glucose and amylase abnormalities. The statement also includes algorithms for a bexarotene protocol and lipid management, which may be used in the clinical setting. CONCLUSION: Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose.
Asunto(s)
Anticarcinógenos/administración & dosificación , Linfoma Cutáneo de Células T/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Tetrahidronaftalenos/administración & dosificación , Adulto , Amilasas/sangre , Anticarcinógenos/efectos adversos , Bexaroteno , Recuento de Células Sanguíneas , Glucemia/metabolismo , HDL-Colesterol/deficiencia , Protocolos Clínicos , Esquema de Medicación , Femenino , Fenofibrato/uso terapéutico , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hipercolesterolemia/prevención & control , Hipertrigliceridemia/inducido químicamente , Hipertrigliceridemia/prevención & control , Hipolipemiantes/uso terapéutico , Pruebas de Función Hepática , Dolor Musculoesquelético/inducido químicamente , Pancreatitis/inducido químicamente , Embarazo , Complicaciones del Embarazo/inducido químicamente , Complicaciones del Embarazo/prevención & control , Tetrahidronaftalenos/efectos adversos , Tirotropina/deficiencia , Tiroxina/uso terapéuticoRESUMEN
BACKGROUND: Fumaric acid esters (FAE) are used in Germany as a first-line systemic treatment for chronic plaque psoriasis, with proven efficacy and low toxicity. Their use in the U.K. is variable, and they remain unlicensed. Consequently, efficacy and safety data from U.K. patients is limited and their place in the psoriasis treatment armamentarium is unclear. OBJECTIVES: To examine the efficacy and safety of FAE in a prospective cohort of U.K. patients with severe, treatment-recalcitrant, chronic plaque psoriasis. METHODS: A single-centre, open, nonrandomized, prospective study was performed in a regional referral centre for patients with severe psoriasis. Outcomes were measured by the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), blood investigations and adverse events monitoring. RESULTS: Eighty patients were recruited. Fifty-nine per cent were taking a concomitant oral antipsoriatic agent; 20% achieved a PASI-50, 8% a PASI-75 and 4% a PASI-90 on intention-to-treat analysis at 3 months with an overall, statistically significant, reduction in PASI from 13.9 + or - 9.0 to 11.3 + or - 9.2 (P < 0.0001). At 3 months, lymphopenia was seen in 33% of the cohort with significantly lower counts in patients responsive to FAE (P = 0.008). In addition, by 3 months, 36% of concomitant antipsoriatic medication had been stopped and 25% of doses had been reduced without loss of disease control. Side-effects (most commonly diarrhoea, abdominal pain and flushing) were reported by 74% of patients resulting in cessation of FAE in 36%. CONCLUSIONS: FAE is a useful alternative treatment option in patients with severe, treatment-resistant, chronic plaque psoriasis and can allow dose reduction, and subsequent cessation, of other, potentially more toxic agents.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Fumaratos/uso terapéutico , Psoriasis/tratamiento farmacológico , Adulto , Anciano , Enfermedad Crónica , Estudios de Cohortes , Fármacos Dermatológicos/efectos adversos , Dimetilfumarato , Femenino , Fumaratos/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenAsunto(s)
Erupciones por Medicamentos/etiología , Exantema/inducido químicamente , Enfermedades Cutáneas Vesiculoampollosas/inducido químicamente , Enfermedad Aguda , Preescolar , Diagnóstico Diferencial , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/patología , Exantema/diagnóstico , Humanos , Masculino , Enfermedades Cutáneas Vesiculoampollosas/diagnósticoRESUMEN
Necrobiotic xanthogranuloma is a rare cutaneous condition that can be mistaken for atypical necrobiosis lipoidica. It has a strong association with a paraproteinaemia, which may progress to frank haematological malignancy. We describe four patients with variable cutaneous features, and their treatment response.
Asunto(s)
Granuloma/diagnóstico , Trastornos Necrobióticos/diagnóstico , Xantomatosis/diagnóstico , Anciano , Anciano de 80 o más Años , Antineoplásicos Alquilantes/uso terapéutico , Clorambucilo/uso terapéutico , Ciclofosfamida/uso terapéutico , Femenino , Granuloma/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Trastornos Necrobióticos/tratamiento farmacológico , Esteroides/uso terapéutico , Resultado del Tratamiento , Xantomatosis/tratamiento farmacológicoRESUMEN
Involvement of the oral mucosa in cutaneous T-cell lymphoma is uncommon and is usually associated with a poor prognosis (the majority of patients dying from the disease within 3 years of the diagnosis of oral involvement). We report the first case of intraoral mycosis fungoides occurring in a child. In addition, our patient has had intraoral disease for 3 years and is currently systemically well with no evidence of cutaneous or systemic disease progression.